Healthcare Innovations II, 2
Back to All Secondary TrustsPortfolio Holdings by Security (As of Deposit Date)
Ticker | Security Description | Deposit % |
---|---|---|
ACAD | ACADIA Pharmaceuticals Inc. | 3.35 |
AMLX | Amylyx Pharmaceuticals, Inc. | 3.38 |
ARDX | Ardelyx, Inc. | 3.36 |
ARVN | Arvinas, Inc. | 3.39 |
AXSM | Axsome Therapeutics, Inc. | 3.37 |
BBIO | BridgeBio Pharma, Inc. | 3.35 |
GRFS | Grifols, S.A. | 3.31 |
ICPT | Intercept Pharmaceuticals, Inc. | 3.29 |
IMCR | Immunocore Holdings plc | 3.30 |
INCY | Incyte Corporation | 3.32 |
IOVA | Iovance Biotherapeutics, Inc. | 3.35 |
JAZZ | Jazz Pharmaceuticals plc | 3.32 |
KNSA | Kiniksa Pharmaceuticals, Ltd. | 3.33 |
KURA | Kura Oncology, Inc. | 3.28 |
MDGL | Madrigal Pharmaceuticals, Inc. | 3.31 |
MIRM | Mirum Pharmaceuticals, Inc. | 3.34 |
MNKD | MannKind Corporation | 3.26 |
MOR | MorphoSys AG | 3.25 |
PNT | POINT Biopharma Global Inc. | 3.30 |
RARE | Ultragenyx Pharmaceutical Inc. | 3.37 |
RCKT | Rocket Pharmaceuticals, Inc. | 3.41 |
RGNX | REGENXBIO Inc. | 3.54 |
RYTM | Rhythm Pharmaceuticals, Inc. | 3.32 |
SUPN | Supernus Pharmaceuticals, Inc. | 3.26 |
TEVA | Teva Pharmaceutical Industries Ltd. | 3.30 |
TGTX | TG Therapeutics, Inc. | 3.30 |
VRDN | Viridian Therapeutics, Inc. | 3.45 |
VRNA | Verona Pharma plc | 3.30 |
VTRS | Viatris, Inc. | 3.32 |
ZLAB | Zai Lab Limited | 3.27 |
Health Care
Ticker | Security Description | Deposit % |
---|---|---|
ACAD | ACADIA Pharmaceuticals Inc. | 3.35 |
AMLX | Amylyx Pharmaceuticals, Inc. | 3.38 |
ARDX | Ardelyx, Inc. | 3.36 |
ARVN | Arvinas, Inc. | 3.39 |
AXSM | Axsome Therapeutics, Inc. | 3.37 |
BBIO | BridgeBio Pharma, Inc. | 3.35 |
GRFS | Grifols, S.A. | 3.31 |
IMCR | Immunocore Holdings plc | 3.30 |
INCY | Incyte Corporation | 3.32 |
ICPT | Intercept Pharmaceuticals, Inc. | 3.29 |
IOVA | Iovance Biotherapeutics, Inc. | 3.35 |
JAZZ | Jazz Pharmaceuticals plc | 3.32 |
KNSA | Kiniksa Pharmaceuticals, Ltd. | 3.33 |
KURA | Kura Oncology, Inc. | 3.28 |
MDGL | Madrigal Pharmaceuticals, Inc. | 3.31 |
MNKD | MannKind Corporation | 3.26 |
MIRM | Mirum Pharmaceuticals, Inc. | 3.34 |
MOR | MorphoSys AG | 3.25 |
PNT | POINT Biopharma Global Inc. | 3.30 |
RGNX | REGENXBIO Inc. | 3.54 |
RYTM | Rhythm Pharmaceuticals, Inc. | 3.32 |
RCKT | Rocket Pharmaceuticals, Inc. | 3.41 |
SUPN | Supernus Pharmaceuticals, Inc. | 3.26 |
TEVA | Teva Pharmaceutical Industries Ltd. | 3.30 |
TGTX | TG Therapeutics, Inc. | 3.30 |
RARE | Ultragenyx Pharmaceutical Inc. | 3.37 |
VRNA | Verona Pharma plc | 3.30 |
VTRS | Viatris, Inc. | 3.32 |
VRDN | Viridian Therapeutics, Inc. | 3.45 |
ZLAB | Zai Lab Limited | 3.27 |
Summary
Description
-
Trust Name Healthcare Innovations II, 2
-
Trust Symbol STHCBX
-
MS Symbol STHI2
Deposit Data
-
Deposit Date 11/02/2023
-
Termination Date 20251029
-
Minimum Investment 100
-
Distribution Frequency Monthly (if any)
-
Initial Public Offer Price $10.00
-
Historical 12-Month Dist.* 0.0000
CUSIP
-
Cash Cusip 83207N304
-
Reinvest Cusip 83207N312
-
Fee Cash Cusip 83207N320
-
Fee Invest Cusip 83207N338
Documents
*The Historical 12-Month Distribution of Trust Holdings is as of 10/01/2024. If the Trust deposited after, or 90 days prior to, 10/01/2024, the distribution is as of deposit date. The Historical 12-Month Distribution is calculated by taking the weighted average of the regular income distributions paid by the securities included in the trust’s portfolio over the 12 months preceding the trust’s date of deposit reduced to account for the effects of trust fees and expenses. This historical distribution is for illustrative purposes only and is not indicative of amounts that will actually be distributed by the trust. The distributions paid by the trust may be higher or lower than the amount shown above due to factors including, but not limited to, changes in the price of trust units, changes (including reductions) in distributions paid by issuers, changes in actual trust expenses and sales of securities in the portfolio. There is no guarantee that the issuers of the securities included in the trust will pay any distributions in the future.